Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT00001823 |
TitleEvaluation for NCI Surgery Branch Immunotherapy Clinical Research Protocols | 阶段 |
Date Added 1999-11-04 |
地点
Maryland, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05482516 |
TitleEvaluating Novel Therapies in ctDNA Positive GI Cancers | 阶段
第三阶段
|
Date Added 2022-08-01 |
地点
District of Columbia, United States
New Jersey, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Atezolizumab, Bevacizumab, Avastin, Tecentriq |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06060704 |
TitleEnvafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC. | 阶段
第二阶段
|
Date Added 2023-09-29 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Bevacizumab, Envafolimab, Trifluridine/Tipiracil, Avastin, Lonsurf |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT02453620 |
TitleEntinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | 阶段
第 1 阶段
|
Date Added 2015-05-25 |
地点
California, United States
Connecticut, United States Maryland, United States Pennsylvania, United States |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Entinostat, Ipilimumab, Nivolumab, Opdivo, Yervoy |
标签
MSS/ MMRp
|
| NCT ID NCT04017650 |
TitleEncorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | 阶段
Phase 1, Phase 2
|
Date Added 2019-07-12 |
地点
Texas, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
cetuximab, encorafenib, Nivolumab |
标签
MSS/ MMRp
|
| NCT ID NCT06923761 |
TitleEMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial – 1) | 阶段
第 1 阶段
|
Date Added 2025-04-11 |
地点
澳大利亚
法国 西班牙 英国 |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd
|
| NCT ID NCT04853017 |
TitleELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201) | 阶段
第 1 阶段
|
Date Added 2021-04-21 |
地点
California, United States
Colorado, United States Iowa, United States Massachusetts, United States Missouri, United States New York, United States Tennessee, United States Texas, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04730544 |
TitleEfficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer ( NIPISAFE ) | 阶段
第二阶段
|
Date Added 2021-01-29 |
地点
法国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Ipilimumab, Nivolumab |
标签
MSI-H/ MMRd
|
| NCT ID NCT06008119 |
TitleEfficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | 阶段
第三阶段
|
Date Added 2023-08-23 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab, Tunlametinib plus Vemurafenib |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05799443 |
TitleEfficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer | 阶段
第二阶段
|
Date Added 2023-04-05 |
地点 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
尚未招聘
|
药物
cetuximab, Irinotecan Hydrochloride, Tislelizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
